REGARDING THE PROVISION OF DRUGS TOCILIZUMAB (ACTEMRA) AND REMDESIVIR
“The issue of urgent ensuring the availability of medicines for the treatment of coronavirus infection is under the special control of the Government of the Republic of Kazakhstan. As part of the fight against coronavirus infection, the Single Distributor is taking measures to provide the country’s medical organizations with medicines. It is worth noting that the Single Distributor purchases in the amount formed by medical organizations and delivers in accordance with the delivery schedule concluded contracts with medical organizations, “the press service of SK-Pharmacy reports.
Provision of the “Tocilizumab” (Actemra) drug
he single distributor for 2021, as part of the provision of guaranteed medical care and compulsory medical insurance at the stationary level, supplies the drug “Tocilizumab” under the trade name “Actemra” in three dosage forms and dosages. The delivery of the drug to medical organizations is provided in a timely manner according to the schedule. The delivery of the drug to medical organizations is provided in a timely manner according to the schedule.
The purchase of an additional volume of medicines is carried out on the basis of applications from medical organizations of the country to the address of the Single Distributor. A single distributor for 2021, taking into account the additional volume declared by medical organizations, the drug Tocilizumab (Actemra) was purchased in the amount of 7043 vials (taking into account the additional volume, a 2-fold increase compared to the application at the beginning of the year). A single distributor, as of August 3, 2021, delivered 4517 vials to medical organizations of the republic. At the same time, 771 bottles were shipped ahead of schedule.
On August 2, 2021, the Supplier delivered the drug in the amount of 1113 vials to the warehouses of the Single Distributor ahead of schedule. In connection with the epidemiological situation, in order to meet the additional needs of medical organizations, the Single Distributor has worked out the issue of additional supply of Actemra in the amount of 1277 bottles in two dosages. The demand for this drug has increased worldwide due to the increase in the incidence of COVID-19.
To ensure additional applications for the drug from medical organizations, the Single Distributor is considering the issue of purchasing an additional volume of Tocilizumab under direct contracts and other drug delivery mechanisms.
Provision of the “Remdisivir” drug
The drug Remdesivir, lyophilized powder 100 mg, is not included in the AU List for 2021, approved by order of the Ministry of Health of the Republic of Kazakhstan dated July 28, 2020 No.ҚR DSM-90/2020.
At the same time, the Single Distributor for 2020 outside the AU List purchased the drug “Remdesivir, powder for making a solution for intravenous injection of 100 mg” on behalf of the Ministry of Health of the Republic of Kazakhstan in accordance with Chapter 19 of the Rules, as well as an irreducible stock based on the letter of the Ministry of Health of the Republic of Kazakhstan dated August 12, 2020 year No. 12-1-12 / 5011-I.
The drug Remdesivir, lyophilized powder 100 mg, was included in the Clinical protocol for the diagnosis and treatment of COVID-19 coronavirus infections in adults as part of a clinical trial on April 1, 2021. According to the data of the Regional and Public Health Departments of Nur-Sultan, Almaty, and Shymkent, the drug Remdesivir was purchased by medical organizations independently and is available in sufficient quantities. In addition, on the basis of instructions from the Ministry of Health of the Republic of Kazakhstan on July 30, 2021, the Single Distributor purchased an additional 124,707 vials of Remdesivir with a delivery schedule until August 15, 2021.
It should be noted that the drugs “Tocilizumab” and “Remdesivir” are included in the Clinical Protocol for the diagnosis and treatment of COVID-19 coronavirus infection in adults as experimental drugs. That is, it is assigned to the patient only upon signing the informed consent personally or by his legal representative.
The drugs are prescribed on the basis of the decision of the medical council, when the potential benefit of the drug outweighs the potential risk to the patient. At the same time, the drugs “Tocilizumab” and “Remdesivir” are not included in the formed 2-month irreducible supply of drugs for the treatment of COVID-19. The Single Distributor monitors the availability of medicines and medical products in the warehouses of the Single Distributor on an ongoing basis, and the balance in medical organizations.
The purchase of an additional volume of medicines is carried out based on the analysis of consumption by medical organizations and monitoring of residues in SK-Pharmacy warehouses and in medical organizations of the country. On a weekly basis, information is provided to the Ministry of Health of the Republic of Kazakhstan.
At the same time, drawing conclusions from the first wave of the pandemic, in order to quickly and effectively resolve the issue of saturation of hospitals and dispensary centers with all the necessary drugs and medical devices for the treatment of coronavirus infection, operational measures were developed to stabilize